Skip to main content
. Author manuscript; available in PMC: 2013 Apr 18.
Published in final edited form as: Oncogene. 2011 Dec 5;31(42):4559–4566. doi: 10.1038/onc.2011.539

Figure 5. Targeting the KRAS-variant impacts cell survival.

Figure 5

Cell lines with (BG1) and without (CAOV3) the KRAS-variant were treated with siRNA/miRNA combinations that bind selectively to the variant allele. A. Decreased cell survival in the KRAS-variant line, BG1 (p<0.001), with no effect on the non-variant line, CAOV3. B. Decreased KRAS protein expression in BG1 (right) concordant with the decrease in cell survival, with no effect on CAOV3 (left). Different siRNAs are denoted by numbers.